ZURA/ 02/09/2026 · 9:28 AM Wedbush Starts Coverage on Zura Bio with Positive Outlook Wedbush gives Zura Bio an Outperform rating and $15 target, highlighting upcoming clinical catalysts and potential stock growth through 2026.
